The Diabetes Devices Market in North America has been estimated at USD 8.55 billion in 2022. It is projected to reach USD 10.96 billion by 2027, at a CAGR of 5.08% during the forecast period from 2022 to 2027. Diabetes is a group of metabolic disorders, a chronic condition associated with an abnormally high level of sugar (glucose) in the blood. North America currently witnesses 44.3 million people affected with Diabetes, which will reach 60.5 million by 2040.
In the years to come, the WHO has predicted Diabetes as one of the leading causes of death. The increased number of patients with Diabetes has resulted in an increased demand for tools for diabetes care. Often contributing to the development of the global market for diabetes care devices resulted in faster and more effective diagnostic methods. Owing to poor eating habits and lack of physical activity, the geriatric population is particularly susceptible to Diabetes. It has led to increased demand for diabetes care products, driving the growth of the industry.
Besides, increased awareness of diabetes care and similar government actions has driven the growth of the global market for diabetes care devices. Wide-ranging advances in healthcare infrastructure and economic progress have had a favorable impact on the market.
Notwithstanding these market-friendly factors, some restrictions may impede their development. Less awareness of the use of devices in remote and underdeveloped areas in the region may, to some degree, prevent the global market for diabetes care devices. There is also a danger to the industry from the lengthy registration periods and reimbursement problems. One of the other significant factors hindering diabetes care devices' market growth in North America is the low average expenditure on Diabetes per person. Besides, compensation dearth and stringent regulations imposed by the government also restrict the market growth in the region.
Over the past few years, with the exponential increase in the cost related to Diabetes, cost-efficient pen needle development will have a significant impact on the growth of the market for diabetes care devices in North America in the years ahead. Enhancing patent terms for profitable products is an effective method to avoid competition and expand North America's product sales. There are several ways of providing insulin to the body, including needles, insulin pens, and insulin pumps. Besides, the healthcare sector's innovation is pushing competitors for change in insulin delivery systems research and development and provides lucrative growth opportunities to the North America Diabetes Devices market.
This research report on the North America Diabetes Devices Market has been segmented and sub-segmented into the following categories:
Geographically, North America is segmented into the USA and Canadian markets. North America tops the Global Diabetes Devices Market, with the USA contributing the maximum to the North American market share. Many top companies are based in North America, so it provides the majority of the market share. The National Diabetes Prevention Program by the U.S Department of Health & Human Services is a public-private partnership of community organizations, private insurers, employers, government agencies, and health care organizations. They work to establish local evidence-based lifestyle change programs for people at higher risk for type 2 diabetes. In this way, private companies partnering with the public sector will create an enormous scope in expanding the market in North America.
The most promising companies in the North America Diabetes Devices Market profiled in this report are Roche Diagnostics, Johnson & Johnson, Abbott Laboratories, Novo Nordisk, Ascensia, Tandem Terumo.
Access the study in MULTIPLE FORMATS
Purchase options starting from $ 2000
Call us on: +1 888 702 9696 (U.S Toll Free)
Write to us: email@example.com